Currently out of the existing stock ratings of Jack Allen, 14 are a HOLD (29.17%), 34 are a BUY (70.83%).

Jack Allen

Work Performance Price Targets & Ratings Chart

Analyst Jack Allen, currently employed at BAIRD, carries an average stock price target met ratio of 45.11% that have a potential upside of 29.68% achieved within 67 days.

Jack Allen’s has documented 86 price targets and ratings displayed on 15 stocks. The coverage is on the Healthcare sector.

Most recent stock forecast was given on BLUE, Bluebird bio at 16-Dec-2024.

Wall Street Analyst Jack Allen

Analyst best performing recommendations are on CRSP (CRISPR THERAPEUTICS AG).
The best stock recommendation documented was for ACLX (ARCELLX) at 4/13/2023. The price target of $39 was fulfilled within 8 days with a profit of $9.7 (33.11%) receiving and performance score of 41.38.

Average potential price target upside

of $11.16 (25.33%) on ACLX (ARCELLX).
of $2.18 (5.76%) on NTLA (INTELLIA THERAPEUTICS).
of $1.7 (3.37%) on CRSP (CRISPR THERAPEUTICS AG).

ALLO Allogene Therapeutics CLLS Cellectis SA DBTX Decibel Therapeutics FATE Fate Therapeutics INKT Mink Therapeutics TIL Instil Bio TSHA Taysha Gene Therapies VOR Vor Biopharma VYGR Voyager Therapeutics FREQ Frequency Therapeutics ACLX Arcellx CRSP Crispr Therapeutics AG RCOR Renovacor NTLA Intellia Therapeutics BLUE Bluebird bio

Show more stocks

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date

Price targets met ratio

Average potential upside

Average Time (Days) For PT To Be Met

Performance score

Asthika Goonewardene (TRUIST)